MA39305A3 - Dérivés d'éthynyle - Google Patents

Dérivés d'éthynyle

Info

Publication number
MA39305A3
MA39305A3 MA39305A MA39305A MA39305A3 MA 39305 A3 MA39305 A3 MA 39305A3 MA 39305 A MA39305 A MA 39305A MA 39305 A MA39305 A MA 39305A MA 39305 A3 MA39305 A3 MA 39305A3
Authority
MA
Morocco
Prior art keywords
ethynyl derivatives
ethynyl
derivatives
compounds
formula
Prior art date
Application number
MA39305A
Other languages
English (en)
Inventor
Eric Vieira
Georg Jaeschke
Antonio Ricci
Daniel Rueher
Barbara Biemans
Wolfgang Guba
Jean-Marc Plancher
Fionn O`Hara
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39305(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39305A3 publication Critical patent/MA39305A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés de formule i, dans laquelle y est n ou c-r
MA39305A 2014-02-25 2015-02-24 Dérivés d'éthynyle MA39305A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14156461 2014-02-25
PCT/EP2015/053785 WO2015128307A1 (fr) 2014-02-25 2015-02-24 Dérivés d'éthynyle

Publications (1)

Publication Number Publication Date
MA39305A3 true MA39305A3 (fr) 2018-05-31

Family

ID=50151209

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39305A MA39305A3 (fr) 2014-02-25 2015-02-24 Dérivés d'éthynyle

Country Status (31)

Country Link
US (1) US9725416B2 (fr)
EP (1) EP3110802B1 (fr)
JP (1) JP6286577B2 (fr)
KR (1) KR101792452B1 (fr)
CN (1) CN106029649B (fr)
AR (1) AR099529A1 (fr)
AU (1) AU2015222303B2 (fr)
BR (1) BR112016017816A8 (fr)
CA (1) CA2938009A1 (fr)
CL (1) CL2016002064A1 (fr)
CR (1) CR20160384A (fr)
DK (1) DK3110802T3 (fr)
EA (1) EA029261B1 (fr)
ES (1) ES2701167T3 (fr)
HR (1) HRP20182016T1 (fr)
HU (1) HUE041392T2 (fr)
IL (1) IL246842B (fr)
LT (1) LT3110802T (fr)
MA (1) MA39305A3 (fr)
MX (1) MX369819B (fr)
PE (1) PE20161415A1 (fr)
PH (1) PH12016501481B1 (fr)
PL (1) PL3110802T3 (fr)
PT (1) PT3110802T (fr)
RS (1) RS58208B1 (fr)
SG (1) SG11201607010XA (fr)
SI (1) SI3110802T1 (fr)
TW (1) TWI576340B (fr)
UA (1) UA117855C2 (fr)
WO (1) WO2015128307A1 (fr)
ZA (1) ZA201605243B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207481B (zh) 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物
AU2016273751B2 (en) 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
TR201909160T4 (tr) 2015-07-15 2019-07-22 Hoffmann La Roche Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri.
AR105556A1 (es) * 2015-08-03 2017-10-18 Hoffmann La Roche Derivados de etinilo
WO2018015235A1 (fr) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Dérivés d'éthynyle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102740699A (zh) * 2009-09-04 2012-10-17 范德比尔特大学 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法
US8759377B2 (en) * 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
SG11201602029VA (en) * 2013-09-25 2016-04-28 Hoffmann La Roche Ethynyl derivatives
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物

Also Published As

Publication number Publication date
CL2016002064A1 (es) 2017-01-13
JP2017506650A (ja) 2017-03-09
MX369819B (es) 2019-11-22
AU2015222303A1 (en) 2016-09-15
ZA201605243B (en) 2017-09-27
US9725416B2 (en) 2017-08-08
CN106029649B (zh) 2019-02-12
HUE041392T2 (hu) 2019-05-28
LT3110802T (lt) 2018-12-27
EA201691690A1 (ru) 2016-12-30
CR20160384A (es) 2016-11-07
ES2701167T3 (es) 2019-02-21
KR101792452B1 (ko) 2017-11-01
EP3110802B1 (fr) 2018-10-10
AU2015222303B2 (en) 2019-02-28
AR099529A1 (es) 2016-07-27
PH12016501481B1 (en) 2019-11-08
CN106029649A (zh) 2016-10-12
HRP20182016T1 (hr) 2019-01-25
TW201546051A (zh) 2015-12-16
PE20161415A1 (es) 2017-01-06
EA029261B1 (ru) 2018-02-28
KR20160111509A (ko) 2016-09-26
WO2015128307A1 (fr) 2015-09-03
CA2938009A1 (fr) 2015-09-03
PT3110802T (pt) 2018-12-04
PL3110802T3 (pl) 2019-03-29
US20160362383A1 (en) 2016-12-15
SI3110802T1 (sl) 2019-01-31
EP3110802A1 (fr) 2017-01-04
PH12016501481A1 (en) 2016-08-22
UA117855C2 (uk) 2018-10-10
IL246842B (en) 2018-11-29
JP6286577B2 (ja) 2018-02-28
SG11201607010XA (en) 2016-09-29
TWI576340B (zh) 2017-04-01
BR112016017816A8 (pt) 2020-06-30
DK3110802T3 (en) 2019-01-07
MX2016011099A (es) 2016-12-12
RS58208B1 (sr) 2019-03-29

Similar Documents

Publication Publication Date Title
AU2016214496B2 (en) 2-(HET)Aryl-substituted condensed bicyclic Heterocycle Derivatives as pest control agents
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA40301A1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA40302B1 (fr) Dérivés de carbazole
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
EP3389783A4 (fr) Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
MX377277B (es) Derivados de fenoximetilo.
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112015004111A2 (pt) novos derivados bicíclicos
EA201690172A1 (ru) Полиморф ингибиторов syk
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201691141A1 (ru) Соединения против ccr6
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MX2018001991A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
EP3504185A4 (fr) Nouveaux composés de n'-hydroxycarbamimidoyl -1,2,5-oxadiazole substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds